Furthermore, conducting randomized controlled studies to compare the therapeutic efficacy between conventional immunosuppressants (e.g., methotrexate 10–15 mg/week) and novel biologics (e.g., anti-IL-4Rα monoclonal antibodies) in AD patients with comorbid autoimmune diseases will provide crucial evidence-based guidance for clinical decision-making. This evidence concerns the gene IL4R and Alzheimer disease.